Tokyo, Japan

Takeshi Isoyama


 

Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2010-2015

Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: The Innovative Contributions of Takeshi Isoyama

Introduction

Takeshi Isoyama is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address cell proliferative disorders, including cancer. With a total of 5 patents to his name, Isoyama's work is recognized for its potential impact on medical treatments.

Latest Patents

Isoyama's latest patents include innovative compounds that have garnered attention in the pharmaceutical industry. One of his notable inventions is related to substituted imidazopyridinyl-aminopyridine compounds. This invention encompasses methods for synthesizing these compounds and their application in pharmaceutical compositions aimed at treating cell proliferative disorders. Another significant patent involves substituted imidazopyridinyl compounds, which also focuses on synthesis methods and their therapeutic use in combating cancer.

Career Highlights

Throughout his career, Takeshi Isoyama has worked with reputable organizations, including Arqule, Inc. and the UAB Research Foundation. His experience in these companies has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Isoyama has had the opportunity to work alongside notable colleagues such as Mark Anthony Ashwell and Chris Brassard. These collaborations have further enriched his research and development efforts.

Conclusion

Takeshi Isoyama's innovative work in the pharmaceutical sector highlights his commitment to advancing medical science. His patents reflect a dedication to finding effective treatments for serious health conditions, making him a valuable contributor to the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…